CJC-1295 with DAC (CJC-1295 DAC, Modified GRF(1-29) with Drug Affinity Complex)

CJC-1295 with DAC represents an engineering solution to a pharmacological problem: how do you make a peptide last for days instead of minutes? The Drug Affinity Complex (DAC) technology, developed by ConjuChem Biotechnologies (Montreal), uses a reactive lysine derivative that forms a covalent bond with circulating albumin after injection. Once bound to albumin (which has a half-life of approximately 20 days), the CJC-1295 peptide is shielded from enzymatic degradation, extending its functional half-life from about 30 minutes to 6-8 days. The human pharmacokinetic data comes from the ConjuChem clinical program. Teichman et al. (PMID: 16384846) administered single doses of CJC-1295 DAC at 30-60 mcg/kg to healthy adults and measured GH and IGF-1 responses over two weeks. The results were striking: GH levels remained elevated for 6+ days after a single injection, and IGF-1 rose 46-84% above baseline and stayed elevated for 9-11 days. Ionescu et al. (PMID: 16849404) confirmed that repeated weekly dosing over 12 weeks produced sustained, dose-dependent IGF-1 elevation without tachyphylaxis (the response didn't diminish over time). The clinical program ended controversially. A participant in a Phase 2 trial died, and while the cause of death was attributed to a cardiac event, the relationship to CJC-1295 DAC was debated. ConjuChem halted development, and the compound never reached Phase 3. This history is worth knowing because it means CJC-1295 DAC has human PK/PD data but no long-term safety data from a completed clinical program. The key distinction between CJC-1295 with DAC and CJC-1295 without DAC (also called modified GRF 1-29 or mod-GRF) is the pattern of GH release. Without DAC, CJC-1295 has a half-life of about 30 minutes and produces a single GH pulse lasting 1-2 hours, which mimics the body's natural pulsatile GH secretion. With DAC, the half-life extends to days, producing continuous rather than pulsatile GH elevation. There's a reasonable debate about which pattern is physiologically preferable. Proponents of the non-DAC version argue that pulsatile GH release is how the body naturally operates, and continuous stimulation may lead to receptor desensitization or disproportionate side effects. Proponents of the DAC version point to the clinical data showing sustained IGF-1 elevation without tachyphylaxis and the practical advantage of less frequent dosing. In practice, the side effects with CJC-1295 DAC tend to be more pronounced than with the non-DAC version. Water retention, joint stiffness, and numbness/tingling are more common because GH elevation is sustained rather than transient. Starting at a lower dose (1 mg weekly) and titrating based on tolerance and IGF-1 levels is a reasonable approach. Cost is moderate at $80-200/month, making it more expensive than basic GH secretagogues like GHRP-6 but cheaper than tesamorelin. The less frequent dosing (1-2 injections per week vs. 2-3 daily injections for short-acting secretagogues) is a significant practical advantage for adherence. The compound was reinstated for compounding under the Feb 2026 HHS ruling and is available from compounding pharmacies with a prescription.